Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 1(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00938288Phase 1Completed

A Study of KW-3357 in Congenital Antithrombin Deficiency

Role: collaborator

NCT00457782Phase 1Completed

A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma

Role: collaborator

NCT00199394Phase 3Completed

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

Role: collaborator

NCT00199368Phase 3Completed

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

Role: collaborator

NCT04404933Completed

Study of Opioid-Induced Constipation 2 Project

Role: collaborator

NCT04350112Completed

Study of Opioid-Induced Constipation 1 Project

Role: collaborator

All 6 trials loaded